Moderna reaches "landmark moment" in Melanoma vaccine trial
First publishedAug 19, 17:08 UTC
Last updatedAug 20, 19:00 UTC · 9m ago
2 outlets
Seattle Times, Fortune1 outlet
MarketWatch1 outlet
Axios1 outlet
Al Jazeera1 outlet
NBC News1 outlet
CBS News1 outletCBS News1 outlet
NPR Health1 outlet
PBS NewsHour
10 outlets over time — hover a bar for its window & outletslast updated
Answer
Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors.
Reported by 10 outlets — PBS NewsHour, NPR Health, CBS News, NBC News, Al Jazeera, and 4 more. See all sources ↓
Read the full report at PBS NewsHour ↗
Why it matters
10 outlets are covering this world story — one to watch as reporting develops.
In brief
- What's the story?
- Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors.
- How widely is it covered?
- 10 outlets, average source rating 7.3/10.
- When was it last updated?
- 9m ago.
Different angles across outlets
Coverage map
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card9 outlets1CoverageScouting report
Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring
Sources9TypeCoverage
Sources (10)
Avg source rating 7.3/10
Processing cluster
A1A2A3B1B2B3